Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Common Equity (2020 - 2025)

Gain Therapeutics has reported Common Equity over the past 6 years, most recently at $5.9 million for Q3 2025.

  • Quarterly results put Common Equity at $5.9 million for Q3 2025, down 33.67% from a year ago — trailing twelve months through Sep 2025 was $5.9 million (down 33.67% YoY), and the annual figure for FY2024 was $7.3 million, down 41.65%.
  • Common Equity for Q3 2025 was $5.9 million at Gain Therapeutics, up from $3.7 million in the prior quarter.
  • Over the last five years, Common Equity for GANX hit a ceiling of $44.5 million in Q1 2021 and a floor of $3.7 million in Q2 2025.
  • Median Common Equity over the past 5 years was $12.6 million (2023), compared with a mean of $18.8 million.
  • Biggest five-year swings in Common Equity: soared 63059.1% in 2021 and later plummeted 68.64% in 2025.
  • Gain Therapeutics' Common Equity stood at $34.8 million in 2021, then tumbled by 45.78% to $18.9 million in 2022, then tumbled by 33.38% to $12.6 million in 2023, then tumbled by 41.65% to $7.3 million in 2024, then fell by 19.49% to $5.9 million in 2025.
  • The last three reported values for Common Equity were $5.9 million (Q3 2025), $3.7 million (Q2 2025), and $5.8 million (Q1 2025) per Business Quant data.